Potential blockbuster AZ immunotherapy secures FDA approval
pharmafile | May 2, 2017 | News story | Manufacturing and Production, Sales and Marketing | AstraZeneca, bladder cancer, darzalex
The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or metastatic urothelial carcinoma – better known as bladder cancer – in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
The approval means AZ can now take the fight to rivals BMS and Roche who are already taking advantage of the small market. Imfinzi presents sizeable benefits to previously untreated patients, for whom the drug is currently undergoing trials, due to release results later in the year. AZ has high hopes for the drug, expecting sales to eventually make it into the billions.
By the terms of the accelerated approval, AZ is required to continue an ongoing clinical trial in order to generate enough data to validate the drug’s efficacy. The company revealed that the average cost of wholesale acquisition will be approximately $15,000 per month.
AstraZeneca Chief Executive Pascal Soriot called the decision “an important milestone in our return to growth”, while a statement from the firm read: “Imfinzi is approved under the FDA’s accelerated approval pathway, based on tumour response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.”
Matt Fellows
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
